Companies
ReiThera
Rome-based viral-vector CDMO built by the Okairos founding team after GSK's 2014 acquisition of Okairos; GMP development and manufacture of adenoviral (GRAd), MVA and AAV vectors for genetic vaccines and advanced therapies.
- Country
- Italy
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | 2014 — continued by the Okairos founding team after GSK acquired Okairos | reithera.com |
| Headquarters | Rome, Italy (Via di Castel Romano 100) | reithera.com |
| Production site | GMP site in Rome with six independent GMP suites (3,470 m2) for clinical-grade ATMP production | reithera.com |
| Capacity | Up to 2,000 L bioreactor capacity and 3,500 vials per batch fill-finish | reithera.com |
| Partnership | Validated its ChAd/GRAd adenoviral platforms with GSK and in large COVID-19 vaccine trials | reithera.com · nature.com |
Independent sources: nature.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Adenoviral vector gene therapy | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.